Phase 2 Study of Exercise Therapy Effects on Progression Markers in Men with Localized Prostate Cancer on Active Surveillance

What this Trial Is About

Researchers are examining how exercise therapy affects specific molecular, radiologic, and pathologic signs related to prostate cancer in men who have low-risk localized prostate cancer and are on active surveillance. This Phase 2 trial compares the effects of a structured exercise program to usual care without providing any direct cancer treatment. The study focuses on men who are inactive and monitors changes in cancer indicators over time. Participants will be assigned randomly to either an exercise therapy group or a usual care group. The exercise intervention involves individualized home-based treadmill walking sessions with a non-linear dosing schedule, progressing up to five sessions per week totaling 225 to 300 minutes weekly. This therapy continues until the participants next standard prostate biopsy, approximately 6 to 12 months after starting. The usual care group continues their normal exercise routines without intervention. During the study, participants will be monitored through molecular, radiologic, and pathologic evaluations to track changes in cancer-related markers from baseline to follow-up over 6 to 12 months. Exercise adherence will be assessed with remote activity and heart rate tracking. Safety evaluations include screening by an exercise physiologist and clearance for exercise participation. The total participation time covers the treatment period until the next biopsy, with continued observation of cancer indicators.

A Study on the Effects of Exercise Therapy on Signs of Prostate Cancer